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Genetic variations of bile salt transporters as predisposing
factors for drug-induced cholestasis, intrahepatic
cholestasis of pregnancy and therapeutic response of viral
hepatitis
Abstract
INTRODUCTION: Drug-induced cholestasis, intrahepatic cholestasis of pregnancy and viral
hepatitis are acquired forms of liver disease. Cholestasis is a pathophysiologic state with
impaired bile formation and subsequent accumulation of bile salts in hepatocytes. The bile salt
export pump (BSEP) (ABCB11) is the key export system for bile salts from hepatocytes.
AREAS COVERED: This article provides an introduction into the physiology of bile formation
followed by a summary of the current knowledge on the key bile salt transporters, namely, the
sodium-taurocholate co-transporting polypeptide NTCP, the organic anion transporting
polypeptides (OATPs), BSEP and the multi-drug resistance protein 3. The pathophysiologic
consequences of altered functions of these transporters, with an emphasis on molecular and
genetic aspects, are then discussed. EXPERT OPINION: Knowledge of the role of
hepatocellullar transporters, especially BSEP, in acquired cholestasis is continuously
increasing. A common variant of BSEP (p.V444A) is now a well-established susceptibility
factor for acquired cholestasis and recent evidence suggests that the same variant also
influences the therapeutic response and disease progression of viral hepatitis C. Studies in
large independent cohorts are now needed to confirm the relevance of p.V444A. Genome-wide
association studies should lead to the identification of additional genetic factors underlying
cholestatic liver disease.
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Genetic Variations of Bile Salt Transporters as Predisposing Factors for 
Drug Induced Cholestasis, Intrahepatic Cholestais of Pregnancy and 
Therapeutic Response of Viral Hepatitis 
 
Abstract 
Introduction: Drug induced cholestasis, intrahepatic cholestasis of pregnancy and viral 
hepatitis are acquired forms of liver disease. Cholestasis is a pathophysiologic state with 
impaired bile formation and subsequent accumulation of bile salts in hepatocytes. The bile 
salt export pump BSEP(ABCB11) is the key export system for bile acids from hepatocytes.  
Areas covered in this review: An introduction into physiology of bile formation is followed 
by a summary on the current knowledge on the key bile salt transporters, namely the sodium-
taurocholate cotransporting polypeptide NTCP, the organic anion transporting polypeptides 
(OATPs), BSEP and the multidrug resistance protein 3 (MDR3). The pathophysiologic 
consequences of altered functions of these transporters, with an emphasis on molecular and 
genetic aspects are covered. 
Expert opinion: Knowledge on the role of hepatocellullar transporters, especially BSEP, in 
acquired cholestasis is continuously increasing. A common variant of BSEP (p.V444A) is 
now a well established susceptibility factor for acquired cholestasis and recent evidence 
suggests that the same variant also influences the therapeutic response and disease 
progression of viral hepatitis C. Studies in large independent cohorts are now needed to 
confirm the relevance of p.V444A. Genome wide association studies should lead to the 
identification of additional genetic factors underlying cholestatic liver disease. 
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Article highlights 
• The bile salt export pump BSEP is the key bile salt exporter in hepatocytes and drives 
the enterohepatic circulation of bile salts. 
• Interference with the function of BSEP, e.g. by inhibition with drugs or steroid 
metabolites leads to an accumulation of bile salts within hepatocytes, which if 
sustained will lead to acquired liver disease. 
• The c.1131T>C polymorphism in the gene coding for BSEP has been identified as a 
susceptibility factor for acquired cholestatic liver disease in independent cohorts. 
• The c.1131T>C polymorphism and subsequent bile acid retention have been identified 
as host factors affecting fibrosis progression and therapy response in chronic viral 
hepatitis C infection. 
• Additional genetic factors need to be identified for increasing the knowledge on 
pathogenetic mechanisms of drug induced cholestasis. 
• The interplay of genetic variants of uptake transporters with genetic factors regulating 
BSEP expression and function needs to be investigated. 
 
1. Physiology of bile formation 
1.1. Introduction 
The exclusive entry site for food and the major entry site for xenobiotics into our body is the 
oral route. Therefore, the small intestine plays a key role in the absorption of nutrients and for 
the delivery of many drugs. From the small intestine, substances are transported via the portal 
blood to the liver. In the liver, they are either retained or let into the systemic circulation. 
Hence, the liver is strategically located between the gut and the systemic circulation and 
constitutes, after the gut, a second barrier controlling access of dietary components to the 
systemic circulation [1]. In the small intestine, dietary components need to be processed for 
absorption, whereby fat requires bile salts for its digestion and absorption. Bile is produced by 
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the liver and delivered via the bile ducts and the gall bladder to the small intestine [2, 3]. 
Major components of bile are bile salts, lipids (phosphatidylcholine and cholesterol), organic 
anions (conjugated bilirubin and others) and small ions [4]. Hepatic bile flow is composed of 
bile salt-dependent bile flow, driven by bile salt secretion and bile salt-independent bile flow, 
which is maintained by hepatocellular secretion of organic anions and the secretory action of 
the bile duct epithelium [5, 6]. 
 
Overall, bile salts are absorbed to more than 90 % in the small intestine and shipped back to 
the liver via the portal circulation, where they are taken up into hepatocytes for a new 
secretion into the biliary tree [7]. This cycling between the gut and the liver is named 
enterohepatic circulation of bile salts. Hepatocytes are equipped with an elaborate tool box for 
an efficient uptake of bile salts from the sinusoids and their export into the canaliculi as well 
as for tightly controlling intracellular concentrations of bile salts [6-15] (Figure 1). Bile salts 
are amphipathic and have detergent properties [3]. Disturbed bile salt secretion by hepatocytes 
is called cholestasis and has far reaching consequences. If bile salts accumulate within 
hepatocytes they become due to their cytotoxicity damaging or even lethal to the cells [16-
18].  
 
1.2. hepatocellular bile salt transporters 
Uptake of bile salts into hepatocytes occurs predominantly in a sodium-dependent manner and 
to a minor extent via sodium-independent processes [11, 15, 19]. Sodium-dependent uptake of 
bile salts is mediated by the sodium-taurocholate cotransporting polypeptide NTCP 
(SLC10A1). This transporter prefers conjugated over unconjugated bile salts [7, 20]. Organic 
anion transporting polypeptides or OATPs (SLCOs) foster sodium-independent uptake of bile 
salts and show a marked preference for unconjugated bile salts [8, 9, 21]. In human liver, 
three OATPs are expressed: OATP1B1 and OATP1B3 transport uncojugated and conjugated 
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bile salts in vitro, while OATP2B1 does not mediate transport of conjugated bile salts [8, 21]. 
The intracellular transport of bile salts from the basolateral membrane to the canalicular 
membrane is not understood in detail, but cytoplasmic binding proteins are almost certainly 
involved [22, 23]. The rate limiting step in bile salt transport from the sinusoidal blood 
plasma into the canaliculus is located at the canalicular plasma membrane [8, 24]. Canalicular 
export of bile salts occurs against a steep concentration gradient and is mediated by the bile 
salt export pump BSEP (ABCB11), which is a member of the ATP-binding cassette (ABC) 
transporter super family [7, 11, 15, 25, 26]. As a consequence, proper activity and regulation 
of BSEP is essential for keeping the potentially cytotoxic bile salts at a low intracellular level 
in hepatocytes. Given their high rate of canalicular secretion and their high concentration in 
bile, bile salts are a crucial driving force for canalicular bile flow. As it is the sole bile salt 
export system, BSEP constitutes the rate-limiting step of hepatocellular bile salt secretion [15, 
25]. Bile flow is further maintained by the secretion of organic anions by the multidrug 
resistance associated protein 2 (MRP2), which contributes to bile salt independent bile flow 
[4]. Any reduction of total bile flow represents a pathophysiologic situation and is called 
cholestasis. 
 
As bile salts are potentially cytotoxic, NTCP expression and function is controlled at the 
transcriptional and posttranscriptional level for regulating the influx of bile salts into 
hepatocytes. The bile salt level in hepatocytes is monitored by the nuclear transcription factor 
farnesoid X receptor (FXR, NR1H4) (table 1) [12]. Increasing intracellular bile salt levels, 
e.g. as a consequence of cholestasis, lead via FXR to an upregulation of the small heterodimer 
partner 1 (SHP-1, NR0B2) (table 1), which in turn represses SLC10A1 (Figure 1). The 
molecular mechanism of SHP-1 mediated SLC10A1 repression is species-dependent [12]. 
NTCP is a phosphoprotein and its state of phosphorlyation regulates recycling of the 
transporter between an endosomal compartment and the basolateral plasma membrane. 
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Increasing cAMP induces dephosphorylation of NTCP in the endosomal compartment. From 
here, NTCP is translocated to the basolateral domain of hepatocytes in a process involving 
rab4 [27, 28]. 
 
OATPs display a broad and overlapping substrate pattern and transport endogenous substrates 
such as conjugated and unconjugated bile salts and metabolic end products. Examples of 
endogenous substrates and metabolic end products are bilirubin, estrone-3-sulfate, tyroxin and 
thyroxin sulfates [21, 29]. 
 
Hepatic OATPs are regulated at the transcriptional and posttranscriptional level. FXR controls 
the transcription of SLCO1B3 directly and the transcription of SLCO1B1 indirectly by a SHP-
1 induced repression of hepatocyte nuclear factor 1α (HNF1α)(table 1). The latter 
transcription factor is the major activator of the SLCO1B1 promotor and also stimulates 
SLCO1B3 [12, 30]. Even though, OATP are key hepatocellular drug transporters (see below), 
only little information is available on the role of ligands for transcription factors activated by 
xenobiotics, such as the constitutive androstane receptor (CAR) or the pregnane X receptor 
(PXR). Expression of SLCO1B3 is downegulated the CAR ligand phenobarbital (table 1) [30]. 
Recently, modulation of the transport activity of OATP1B1 and OATP1B3 has been 
demonstrated for a variety of PXR ligands [31] and by physiologic substrates such as 
prostaglandins [32] or estrone-3-sulfate [33]. OATPs are subjected to phosphorylation, 
leading in the case of OATP1B1 to an increased plasma membrane localization [34] and in 
the case of OATP2B1 to an internalization from the plasma membrane [35]. 
 
BSEP transports almost exclusively monoanionic, conjugated bile salts, but displays species-
dependent substrate specificity [15, 25, 26]. Rat Bsep barely transports unconjugated bile 
acids [36]. The same holds true for BSEP, as patients with defective bile acid conjugation 
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have very little unconjugated bile salts in their bile [37]. Mutations in the gene coding for 
BSEP lead often to severe liver disease [38]. 
 
At the transcriptional level, BSEP is under strong positive control by FXR [12, 26], which 
needs to interact with its nuclear receptor retinoid X receptor (RXR, NR2B1) forming a 
heterodimeric complex (Figure 1, table 1) [12, 39]. The activation of FXR is more 
pronounced with hydrophobic than with hydrophilic bile salts [12, 40] with 
chenodeoxycholate having an EC50 value of 50 µM for human FXR [41]. At the 
posttranscriptional level, short term regulation of BSEP, involves the modulation of the 
carrier density of BSEP via endo- and exocytosis as well as regulation of its activity by 
changes of the phosphorylation state [42-44]. Additional elements of regulation may involve 
ubiquitinylation and protein-protein interaction [38]. 
 
1.3. Canalicular lipid secretion 
Phosphatidylcholine is the major bililary lipid and requires functional MDR3 (ABCB4) for its 
canalicular secretion [45]. Phosphatidylcholine is released from the canalicular membrane 
into bile by the detergent action of bile salts [46]. Mutations in the gene coding for MDR3 
lead to severe liver disease [47]. In canalicular bile, phosphatidylcholine and bile salts form 
mixed micelles, which then act as acceptors for poorly water-soluble substances, e.g. 
cholesterol [46]. Release of cholesterol from the canalicular membrane into the aqueous 
canalicular bile is facilitated by the heterodimeric ABC transporter ABCG5/ABCG8 [48]. 
Taken together, canalicular lipid secretion requires the coordinated action of three ABC 
transporters, namely BSEP, MDR3 and ABCG5/ABCG8. In addition to providing a biliary 
vehicle for poorly water soluble compounds, mixed micelles are instrumental for lowering the 
toxicity of bile salts against the epithelial cells lining the bile ducts [49]. 
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1.4. Canalicular secretion of organic anions 
In addition to bile salts, organic anions such as bilirubin diglucuronide or glutathione as well 
as drug metabolites conjugated to glucuronide or sulfate are secreted into bile. This secretion 
is maintained by two additional ABC transporters. The multidrug resistance protein 2 (MRP2, 
ABCC2) excretes bilirubindiglucuronide and has a preference for glucuronidated drug 
metabolites [50, 51]. ABCG2 (also called breast cancer resistance protein or BCRP) mediates 
secretion of a variety of metabolites of endogenous and xenobiotic compounds and displays a 
preference for sulfated compounds [51, 52]. It should however be noted that the substrate 
specificities of ABCC2 and ABCG2 show some overlap. 
 
In summary, bile salt secretion is mediated by BSEP and the coordinated interplay between 
several ABC transporters is necessary to keep intracellular bile salt concentrations at a 
nontoxic level and to protect bile ducts against the toxic action of bile salts. Any dysfunction 
of these processes caused either by inherited or acquired functional impairment of these 
canalicular transporters leads to a potential pathophysiologic state of the liver or even to 
clinically relevant liver disease. 
 
2. Bile Salt Transporters as Drug Transporters 
While NTCP is predominantly a bile salt transporter it can handle in addition 
bromosulfophthalein and sulfated steroid metabolites [7, 11, 20, 53]. In addition, human 
NTCP mediates transport of iodothyronine T4 and sulfated thyroid hormone metabolites [54] 
as well as recently demonstrated indocyanine green [55]. Very interestingly, human NTCP 
but not rat Ntcp can transport the statin rosuvastatin [56]. Using isolated human hepatocytes, 
Ho et al. were able to demonstrate that NTCP may mediate up to 35 % of total rosuvastatin 
uptake into hepatocytes, the remainder being imported by OATPs [56]. NTCP may therefore 
also contribute to hepatocellular handling of steroid metabolites and of some drugs. 
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In contrast to NTCP, OATPs are rather drug than bile salt transporters mediating the uptake of 
a multitude of drugs and xenobiotics. The hepatocellular OATPs have a considerable 
overlapping substrate pattern [21, 29, 57, 58]. Among the many drugs transported by OATPs, 
statins are among the most widely used drugs [59]. In heterologous expression systems, where 
transporters can be studied individually, OATPs clearly display overlapping substrate 
specificity. However, prediction of the contribution of individual OATPs to in vivo 
hepatocellular drug uptake is up to now difficult. For example, vitro assays have shown that 
all three hepatocyte OATPs can transport rosuvastatin [60]. Importantly, a recent genome-
wide single nucleotide polymorphism association study however indentified only OATP1B1 
variants as a risk factor for myopathy in a patient population receiving a high-dose 
simvastatin treatment [61]. This can be interpreted that the functionally dominant simvastatin 
uptake system in human hepatocytes is OATP1B1. Part of the uncertainty in extrapolating in 
vitro findings to the in vivo situation may in addition be due to the fact that the transport 
mechanism of OATPs has not been worked out in molecular detail. In general, they are 
believed to be organic anion exchangers working bidrectionally [62]. In addition, recent 
evidence shows that transport activity of many OATPs is enhanced by a low extracellular pH 
63
. Understanding the exact transport mechanism and the driving forces of OATPs is however 
instrumental for determining the role of individual OATPs in hepatocellular drug uptake. 
Knowing the driving force will also allow to predict whether OATPs can accumulate drugs 
within hepatocytes to a concentration higher than in blood plasma. 
 
BSEP has a rather narrow substrate specificity and transports predominantly bile salts and in a 
species dependent manner taurolithocholate-3-sulfate [15, 64]. So far, only pravastatin has 
been identified as a BSEP substrate different from bile salts [15, 65]. Hence, BSEP seems to 
play practically no role in hepatocellular handling of drugs. 
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3. Drug Induced Cholestasis 
Drug induced liver injury is a form of acquired liver disease, is a clinically relevant entity and 
leads to a considerable number of hospitalizations [66-69]. Drug induced liver injury spans a 
wide spectrum of injuries from bland cholestasis to hepatitis including mixed forms [69-72]. 
Bland cholestasis is a consequence of drug induced inhibition of bile salt secretion with 
consequent reduction of bile flow [69, 73]. Any drug leading to cholestasis needs to be taken 
up into hepatocytes, prior to its interference with bile formation. Hence, hepatocellular uptake 
systems, such as for example OATPs are part of the cascade leading to drug induced 
cholestasis. 
 
Often, the underlying pathogenetic mechanisms of drug induced liver injury remain obscure 
and to some extent unpredictable, in particular for idiosyncratic reactions [72, 74]. 
Elucidation of the mechanism is complicated by the fact that both predisposing and 
environmental factors are important. Once rat Bsep was cloned and identified as the most 
important, if not the sole canalicular bile salt export system [36, 75], interaction of drugs 
causing cholestatic liver injury, e.g. cyclosporine [76, 77] could be tested specifically for the 
interaction with Bsep. It was found that cyclosporine, rifamycin SV, rifampicin, 
glibenclamide inhibit rat and human BSEP in a concentration dependent and competitive 
manner [75, 78, 79]. Thereby, the Ki values of Bsep inhibition in the Sf9 cell expression 
system are comparable with the Ki values obtained in isolated rat liver canalicular plasma 
membrane vesicles [75]. Inhibition of Bsep by such drugs leads to intracellular retention of 
bile salts in hepatocytes with ongoing and increasing elevation exerting cytotoxic reactions to 
hepatocytes [16]. Bosentan is a dual endothelin receptor antagonist and is predominantly 
eliminated by biliary excretion [80, 81]. Hepatocellular uptake of bosentan and its metabolite 
occurs via OATP1B1 and OATP1B3 [82]. Bosentan caused in clinical trials, asymptomatic, 
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reversible transaminase elevations in some patients with a dose dependent incidence [83]. 
Importantly individuals, who were on glyburide and bosentan showed a higher incidence of 
liver injury compared to patients with bosentan monotherapy. Bosentan is a competitive 
inhibitor of rat and human BSEP expressed in Sf9 cell vesicles [79, 83]. Experiments with 
rats, which were treated with bosentan and glyburide together provide strong in vivo evidence 
that a specific interaction of bosentan with BSEP is responsible for the observed liver injuries 
[69, 73, 83]. Interestingly, a follow-up study in rats it demonstrated that canalicular 
expression of functional Mrp2 is necessary for the cholestatic action of bosentan [84]. In rats, 
bosentan stimulates via Mrp2 canalicular bile flow, which in turn impairs canalicular lipid 
secretion [85]. In vitro studies with rat and human Mrp2/MRP2 displayed a stimulation of 
MRP2 transport activity and confirmed the inhibition of rat and human Bsep/BSEP by 
bosentan [86].To summarize, the example of bosentan shows that drugs do not only impair 
Bsep function via direct inhibition, but can affect its activity also indirectly in the canalicular 
membrane by processes involving Mrp2 [69, 73] Indirect drug interaction with BSEP has also 
been shown for estradiol-17β-glucuronide and for the HER1/HER2 inhibitor PKI166 [75, 87]. 
 
Other examples of MRP2 activation include sulfinpyrazone, penicillin G or indomethacin 
[88]. The consequence of drug-induced activation of MRP2 may be a lowering of the bile salt 
concentration in the canaliculus below a (yet unknown) threshold value followed by an 
alteration in canaliculaur phospholipid and cholesterol secretion [85]. Taken together, BSEP 
can either be inhibited directly by drugs form the cytoplasm or indirectly, most probably from 
the canalicular side. This latter process seems to need the presence of functional MRP2. 
 
Bland cholestasis caused by BSEP inhibition is rapidly reversible upon discontinuation of the 
drug, as exemplified with bosentan [83]. On the other hand, if additional toxic mechanisms 
are involved, liver injury may persist after cessation of the drug or display a delayed onset. An 
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example for this is troglitazone, which is together with a metabolite inhibits BSEP and exerts 
via metabolites toxicity to mitochondria [69, 73, 89, 90]. 
 
In conclusion, an increasing number of drugs or their metabolites is being identified as having 
the potential to interfere with transport activity of BSEP [15, 73, 91]. As alteration of BSEP 
activity includes direct and indirect mechanisms (figure 1), the actual molecular mechanism 
of drug induced reduction of BSEP activity may be complex and hard to predict for a given 
substance. 
 
4. Intrahepatic Cholestasis of Pregnancy 
Intrahepatic cholestasis of pregnancy occurs usually in the second or third trimester of 
pregnancy in otherwise healthy women and belongs to the acquired forms of cholestasis [92-
95]. The incidence shows a wide geographic variability and is averaging between 0.5 to 1.5 % 
in Caucasians in Europe and the United States [95]. Clinical evidence shows a link between 
serum levels of estrogens and in particular progesterone and its metabolites and the 
pathogenesis of cholestasis of pregnancy [96-100]. In addition, oral contraceptives can cause 
cholestasis, too [99, 101]. Treatment of rats with the steroid metabolites estradiol-17β-
glucuronide or progesterone sulfate leads to an acute cholestasis, supporting a role of steroid 
metabolites in cholestasis of pregnancy [102, 103]. Animal studies, summarized in [69] 
revealed that treatment of the animals with high doses of ethinylestradiol over 5 days lead to 
cholestasis, which is paralleled by a down-regulation of hepatocellular uptake transporters for 
bile salts and of the canalicular efflux transporters Mrp2 and Bsep [104, 105] and reduced 
transport activity [106]. The acute cholestatic effect of estradiol-17β-glucuronide requires 
functional Mrp2 in the canalicular membrane of rats [107]. In addition, a bolus injection of 
estradiol-17β-glucuronide leads to a rapid retrieval of part of Bsep and Mrp2 from the 
canalicualar membrane into a subapical compartment [108] (Figure 1). Finally, estradiol-17β-
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glucuronide and progesterone-sulfate are indirect inhibitors of Bsep requiring the 
coexpression of Mrp2 [75, 102, 109]. As an alternate and/or additional mechanism, Bsep 
inhibition via a physical interaction between Mrp2 and Bsep in the canalicular membrane, 
which is stimulated by estradiol-17β-glucuronide has been suggested [107]. Hence, the 
pathogenesis of estrogen induced cholestasis as a model for cholestasis of pregnancy is 
clearly multifactorial ranging from the transcriptional to the post-transcriptional level and 
ending with indirect transporter inhibition. 
 
5. Pharmacogenetics of transcription factors 
So far, a limited number of studies on the pharmacogenetics of FXR have been performed. A 
study involving Americans from European, African, Hispanic and Chinese descent identified 
a polymorphism at c.-1G>T with frequences ranging from 2.5 to 21.1 % [110]. Analysis of 
gene expression revealed that this polymorphism leads to a significantly lower expression of 
the FXR target genes coding for SHP-1, OATP1B1 and OATP1B3. In addition, four non-
synonymous polymorphisms with frequencies of less than 1 % were reported in this study. An 
independent study also identified the c.-1G>T polymorphism [111] and demonstrated that this 
polymorphism leads to a reduced transcriptional activity in a luciferase reporter assay. In 
addition, three non-synonymous polymorphisms different from the other study were reported. 
Lately, additional polymorphisms in the FXR gene were identified and an intronic 
polymorphism was associated with the body mass index [112] and a haplotype was associated 
with gallstone prevalence [113]. 
 
6. Pharmacogenetics of Drug Induced Cholestasis 
Investigation of the contribution of genetics to drug induced cholestasis and other forms of 
liver injury is challenging due to the low incidence of this disease. Progress in this area as 
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well as in genetics of drug response has however in recent years began to speed up by using 
the candidate-gene approach or by genome-wide association studies [69, 72, 114-117]. 
 
Recently, an elegant genome wide association study with patients treated with a high dose 
simvastatin identified with highest statistical significance a polymorphism located in intron 11 
of the SCLO1B1 gene associated with myotoxicity [61] as well as additional polymorphisms 
in the same gene. Of note, the p.V174A polymorphism showed reduced transport activity for 
the prototypic OATP substrates estrone-3-sulfate and estrdiol-17β-glucuronide in a model 
expression system [118]. Hence, the increased incidence of myotoxicity of simvastatin in 
these patients can be explained by a reduced hepatocellular uptake of this drug with 
subsequent higher serum levels. Numerous reviews have summarized the impact of OATP 
polymorphisms on pharmacokinetics and adverse drug reactions [57, 58, 119-124]. In contrast 
to OATPs, little information on the physiologic consequences of NTCP is available. This may 
be due to the fact that the role of NTCP on hepatocellular drug transport is minimal. 
Nevertheless, two nonsynonymous polymorphisms (p.I223T and p.S267F) were identified in 
different ethnicities, whereby very interestingly the p.S267F variant does practically not 
transport taurocholate but displays unaltered transport of estrone-3-sulfate [125]. Later, the 
p.S267F variant was found to be a gain of function variant for rosuvastatin transport [56]. 
This may, in the case of rosuvastatin have an impact on hepatocellular uptake of this drug, as 
NTCP may account for up to 35 % of rosuvastatin uptake into human hepatocytes [56]. 
 
At the efflux side, the impact of genetic alterations in ABCB11 is currently being studied. For 
example, a study including a cohort of 36 patients with drug-induced cholestasis found the 
p.V444A polymorphism of BSEP to be significantly overrepresented in the patient group 
leading to a threefold increased risk of developing drug-induced cholestasis under treatment 
with various drugs [126] (Figure 1). The same study also identified a p.D676Y mutation in a 
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patient receiving fluvastatin. Interestingly, the drugs associated with cholestasis in this cohort 
are not inhibiting the transport activity of BSEP [69]. However, the p.V444A polymorphism 
has been shown to be associated with reduced BSEP protein levels in healthy human liver 
samples 127 and in an in vitro expression system [128]. A recent study found a correlation 
between lower mRNA levels and the p.V444A coding variant of the BSEP gene in a patient 
population, but no correlation between mRNA and BSEP protein levels [129]. It is clear that 
the limited size of the cohorts so far studied does not allow extrapolation into the general 
population with respect to this BSEP polymorphism. In addition, it should be kept in mind 
that the frequency of individual BSEP polymorphisms is ethnicity dependent [130-133]. 
Polymorphisms of BSEP may, in addition to affecting hepatocytes, have systemic effects 
[26]. A large study aimed at correlating in a genome-wide study single nucleotide 
polymorphisms with fasting glucose levels identified two polymorphisms in intron 19 of 
ABCB11 [134]. This may reflect that fact that serum bile salt levels are tightly interconnected 
with energy homeostasis [135, 136]. The genetic study on drug induced cholestasis identified 
a mutation in the BSEP gene in one of the patients, whereby p.D676Y was present as a 
heterozygous allele but displayed normal taurocholate transport activity [126]. In the same 
study, a novel heterozygous mutation was identified in MDR3, p.I764L, which was not 
further characterized. This is to the best of our knowledge the only variant of the ABCB4 
gene, which has been associated with drug induced cholestasis. Even though MRP2 has been 
shown to be necessary for certain substances to inhibit Bsep function, no clear evidence has 
been presented for a role of MRP2 in drug induced cholestasis in humans. Very interestingly 
however, ABCC2 haplotypes have been associated with diclofenac-induced hepatotoxicity 
[137], with toxic liver injury caused by herbal remedies [138] and with nonalcoholic fatty 
liver disease [139].  
 
7. Pharmacogenetics of intrahepatic cholestasis of pregnancy 
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As the incidence of intrahepatic cholestasis of pregnancy shows regional clusters, genetic 
susceptibility factors are very likely to play a role in the pathogenesis of this disease [47, 69, 
117]. Mutations and polymorphisms in the genes coding for BSEP and MDR3 have clearly 
been associated with this disease. The first evidence for a genetic trait in intrahepatic 
cholestasis of pregnancy came from a family, where female members displayed with 
intrahepatic cholestasis of pregnancy and had a mutation in the ABCB4 gene [140]. This 
finding was confirmed and extended in a cohort study comparing genetic variations of the 
ABCB4 gene in women with intrahepatic cholestasis of pregnancy and in women with 
uneventful pregnancies [141]. In this study, close to half of the patients had elevated 
γ−glutamyl transferase, which is a clinical hallmark for liver disorders caused by impaired 
MDR3 function. Of the women with elevated γ-glutamyl transferase, 77 % were carriers of 
disease-specific mutations in the ABCB4 gene. In addition, multiple studies including case 
reports have previously and later reported a defective MDR3 associated with intahepatic 
cholestasis of pregnancy [142-150]. Opposite to this, there are studies, which could not 
identify a role of mutations in ABCB4 in cholestasis of pregnancy, indicating the presence of 
additional susceptibility factors for intrahepatic cholestasis of pregnancy [151, 152]. 
 
Indeed, BSEP came into the spotlight as a susceptibility factor for intrahepatic cholestasis of 
pregnancy [153]. Two studies indicated that the BSEP p.444A variant is significantly 
overrepresented in women with intrahepatic cholestasis of pregnancy [141, 154] (Figure 1). 
Of note, the c.1131T>C polymorphism of the BSEP gene was associated with higher serum 
bile salt levels [154], which may be due to the tendency of lower protein expression levels of 
this BSEP variant [127]. The association of p.444A with intrahepatic cholestasis of pregnancy 
has since been confirmed in two independent cohorts [155]. Additionally, several mutations in 
BSEP have been reported in patients with intrahepatic cholestasis of pregnancy [47, 69, 156]. 
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A cohort study identified in the FXR gene four heterozygous variants, one of which 
(p.M173T) is significantly associated with intrahepatic cholestasis of pregnancy [111]. This 
variant leads to a reduced activity of the BSEP promoter, which most likely will lead to a 
lower BSEP expression level. Finally, a recent report presented a patient suffering from 
intrahepatic cholestasis of pregnancy, which has a c.-1G>T variant of FXR, a p.S320F variant 
of MDR3 and a p.V444A in BSEP [157]. This patient clearly demonstrates that the genetic 
basis of cholestatic liver disease may be complex and in turn also the pathophysiologic 
consequences of the altered genes. 
 
8. Impact of ABCB11 variants on the course of viral hepatitis C 
Recent evidence indicates that bile salts affect the replication of the hepatitis C virus (HCV) 
by suppressing interferon effects in vitro and the therapy response to pegylated interferon in 
patients with chronic HCV infection (Figure 1, table 2). Two independent studies 
demonstrated an activation of HCV replication by bile acids [158, 159]. In both studies, HCV 
RNA expression has been monitored after incubation of HCV genotype 1 replicon-harbouring 
cells with various bile acids. Addition of individual bile acids including deoxycholic acid and 
chenodeoxycholic acid into the medium increased the levels of HCV RNA five- to ten-fold 
while guggulsterone, an antagonist of bile acid receptor farnesoid X receptor (FXR), reduced 
the bile acid-mediated increase of HCV RNA [158, 159]. Furthermore, bile acids significantly 
reduced the anti-HCV effect of either IFN α or γ clearly demonstrating functional relevant 
alterations of the interferon signal [158, 159]. In one study, the specific FXR-dependent 
nature of the bile acid effect on hepatitis C replication has been investigated in more detail 
[159]. FXR ligands stimulated HCV replication while FXR silencing and FXR antagonism by 
guggulsterone blocked the up-regulation induced by bile acids. 
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The effects of bile acids on interferon α effects have also been investigated in patients with 
chronic hepatitis C infection. First observations in small and heterogenous HCV populations 
with different, inferior treatment regimens indicated that accumulation of bile salts may be a 
negative prognostic marker to predict sustained viral response (SVR) [160, 161]. Recently, 
the effects of plasma bile acid levels and a related BSEP gene polymorphism have been 
investigated in a large and well defined cohort of PEG-interferon treated hepatitis C patients 
[162]. Patients experiencing viral clearance had significantly lower bile acid concentrations 
than those without SVR. Significant differences in therapy response according to bile acid 
levels could be detected for a combined HCV genotype 2 and 3 subgroup and with marginal 
statistical significance also for genotype 1 patients. To determine whether BSEP genotypes, 
predisposing to a "cholestatic" phenotype [111, 126, 154, 155, 163], influence the outcome of 
interferon treatment similar to bile acid levels, the p.V444A of BSEP was analyzed. In line 
with elevated bile acid levels in non-SVR patients, an association between SVR and presence 
of the ABCB11 1331C allele (coding for 444A) was observed in the subgroup of HCV 
genotype 2 and 3 infected patients (OR 2.94) but not statistically significant for genotype 1. 
Besides this association to therapy response, a slight but significant difference in the 
frequency of the homozygous1331C BSEP genotype between patients with chronic hepatitis 
C compared to healthy control subjects was identified [162]. This finding supports the 
speculation that the host may also play a causal role via increased bile salt levels for a 
susceptibility to develop chronic HCV infection. On a first view, these in vivo findings are in 
contradiction to the replicon studies where bile acids did not affect replication of HCV 
genotype 2a-JFH1 replicons. However, the three tested replicons were differently sensitive to 
FXR modulation [158, 159]. Nevertheless, the findings in HCV patients are in line with an 
established negative effect of bile acids on interferon signalling and the induction of proteins 
involved in the antiviral activity in cell culture studies [164]. 
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Hepatocellular accumulation of bile acids contributes to an up-regulation of inflammatory 
cytokines and chemokines such as tumor necrosis factor α and monocyte chemotaxis protein-
1 which in turn results in hepatic stellate cell recruitment, and therefore may represent an 
early event in liver fibrogenesis [165]. Therefore, another HCV cohort study investigated 
whether BSEP or FXR genotypes are associated with fibrosis progression and the 
development of cirrhosis as they were with increased bile acid levels [166]. The main finding 
of this study is an association of the BSEP c.1331T>C polymorphism with progression to 
liver cirrhosis with a more than twofold carrier risk in patients with chronic viral hepatitis C. 
Of note, no genetic association of this polymorphism with the presence of advanced fibrosis 
and cirrhosis has been observed in a second independent cohort presenting with non-alcoholic 
fatty liver disease (NAFLD) as a non-viral disease. This leads to the speculation that the 
observed bile acid effects on the presence of cirrhosis could be HCV-specific and may not 
generally apply for chronic liver disease of other non-viral causes. Due to a low allelic 
frequency of the c.-1G>T variant of FXR in Caucasians only 9 heterozygous individuals (all 
without cirrhosis) could be identified carrying this variant, which does not allow definite 
conclusions [166]. 
 
9. Expert Opinion 
The role of BSEP in acquired cholestasis in now well established. Inhibition of BSEP by 
drugs may lead to drug induced cholestasis [73, 75, 78, 79, 83]. Recently, an exhaustive 
screen of more than 200 compounds confirmed that substances inhibiting BSEP and having 
an IC50 value below 25 µM are associated with liver problems in humans [91]. This work 
clearly demonstrates the value of inhibition experiments against BSEP heterologously 
expressed in membrane vesicles during drug development. It should however be pointed out 
that an interference of a new chemical entity with the transport activity of BSEP does not 
necessarily render such a compound obsolete. This point is supported by the fact that 
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cyclosporine is a very potent inhibitor of BSEP in the vesicular test system [75, 91], but 
nevertheless made transplantation of solid organs possible. Another example of a BSEP 
inhibitor is rifampicin (rifampin), which is still very important in treatment of active 
pulmonary tuberculosis [167]. Observation of BSEP inhibition would rather rise a warning 
sign to carefully monitor the function or BSEP later during development, e.g. by following 
serum bile salt levels. From this perspective, clearly more information is needed on 
similarities and/or differences of BSEP in different species [79, 168], such as rats or dogs, 
which are frequently used animals in drug development. 
 
Vesicle studies should be complemented with more complex systems, such as cultured cells, 
displaying both transport and metabolic activity. BSEP inhibition leads to an intracellular 
accumulation of bile salts, which by interfering with mitochondrial function become cytotoxic 
[16]. The example of troglitazone has demonstrated that formation of toxic metabolites in 
combination with BSEP inhibition may lead to severe liver problems. Metabolites of 
troglitazone are directly toxic to mitochondria [89, 90]. Troglitazone and its sulfated 
metabolites are both potent BSEP inhibitors [169]. Hence, in addition to toxic troglitazone 
metabolites elevated bile salts may act on mitochondria and thus synergistically damage them 
[170]. An established model system to investigate bile salt transport and drug metabolism 
simultaneously are sandwich-cultured hepatocytes [171]. A combination of different 
conceptual approaches and experimental model systems is clearly needed, in particular as 
primary cultured hepatocytes tend to dedifferentiate and to develop a cholestatic phenotype 
[172]. 
 
New cellular models are needed to study mechanisms of drug induced liver injury, including 
drug induced cholestasis. In this area, new exciting developments hold great promise. Proof of 
principle has been presented that hepatocyte-like cells can be produced from multipotent 
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mesenchymal stem cells isolated from human umbilical cord blood or from induced 
pluriopotent stem cells [173-176]. The latter should allow to develop hepatocyte cell culture 
models using cells derived from patients with acquired, drug induced cholestasis or other 
forms of liver disease [177]. The advantage of such an approach is the possibility for studying 
the impact of a given genetic background of all systems involved in drug transport, 
metabolism on adverse drug reactions and putting them in perspective to the clinical 
phenotype. 
 
While a lot of progress has already been made in understanding the impact of 
pharmacogenetics on drug and bile salt transport, as well as on the role of BSEP in 
susceptibility to acquired liver disease [69, 178], more work is needed in this area. First, while 
there is now considerable evidence that the p.V444A polymorphism is associated with an 
increased risk of acquired cholestasis, the identification of additional factors is necessary. 
Given the almost equal distribution of the two alleles with frequencies around 50 % in 
different populations and the much lower incidence of drug-induced cholestasis, additional 
susceptibility factors are involved. One possible way to identify novel factors will be genome 
wide association studies in cohorts of patients suffering from drug-induced cholestasis. It is 
important to keep in mind that any drug interfering with cananlicular bile formation first 
needs to enter hepatocytes, before it reaches the canaliculus. Hence, more information is 
needed on the impact of genetic variability of hepatocellular uptake systems. While some 
transporters, such as for example OATP1B1 [57, 179] are well studied, information on others, 
such as for example OATP2B1 or OATP1B3 has just started to emerge [180, 181]. In 
addition, the driving force for OATPs has not yet been fully worked out [29]. Evidence has 
been presented that a large number of OATPs are stimulated by a slightly acidic extracellular 
pH [63]. This brings the importance of the microclimate of a transporter into the spotlight. 
Hence, more research is needed both at the mechanistic as well as at the genetic level of drug 
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transporters, not to mention that so far no structure of an uptake drug transporter has been 
resolved. 
 
Finally, understanding the impact of BSEP polymorphisms on the natural course of acquired 
chronic liver disease is currently emerging. Recent evidence points to a relevant interference 
with the interferon therapy in patients with chronic hepatitis C infection [162]. Furthermore, 
data from this study with an overrepresentation of the respective BSEP polymorphism also 
point to a potential role of bile salt retention on the development of chronic viral disease 
during acute infection and have been confirmed by other groups. The molecular mechanism 
by which bile salts affect the HCV replication are still unknown. For future research, the 
differential response of distinct replicons to bile salt-mediated signals should provide a unique 
clue for mapping the region bearing HCV sensitivity to FXR on the viral genome [159]. 
However, bile salt-dependent effects on the natural course of chronic liver disease must be 
interpreted strictly in the disease-specific pathophysiological context since the ABCB11 
c.1331T>C polymorphism is associated with fibrosis in chronic hepatitis C patients but not in 
those with fatty liver disease [166]. More information on the particular role of bile acid 
retention on insulin resistance accompanying fatty liver disease and other clinically relevant 
disease entities such as hepatocellular carcinoma are expected in the near future. 
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Table 1: Main transcription factors regulating the expression of hepatocellular transporter 
genes 
Transporter Gene 
(Transporter Protein) 
Nuclear Receptor (Nuclear 
Receptor Gene) 
Receptor Ligands 
SLC10A1 (NTCP) SHP-1 (NR0B2) regulated by 
FXR 
FXR (NR1H4) 
 
 
hydrophobic bile acids, 
GW4064 
SLCO1B1 (OATP1B1) HNF1α (TCF1) regulated by 
SHP-1 FXR cascade 
SHP-1 (NR0B2) 
FXR (NR1H4) 
 
 
 
hydrophobic bile acids, 
GW4064 
SLCO1B3 (OATP1B3) HNF1α (TCF1) 
FXR (NR1H4) 
 
CAR(NR1I2) 
 
hydrophobic bile acids, 
GW4064 
bilirubin, Phenobarbital 
TCOBOP, androstenol 
(antagonist) 
ABCB11 (BSEP) FXR (NR1H4) 
 
RXR (NR2B1) (obligate 
heterodimeric partner for 
class II nuclear receptors 
hydrophobic bile acids, 
GW4064 
9-cis retinoic acid, rexinoids 
 
Page 72 of 75
URL: http://mc.manuscriptcentral.com/eomt  Email: david.grech@informa.com
Expert Opinion On Drug Metabolism & Toxicology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 41 
Table 2: Effect of bile salts on viral hepatitis C  
Effect Study System Reference 
inhibiton of interferone response HepG2 cells [164] 
lower levels of serum bile salts in 
sustained responders than in non-
repsonders and relapsing patients 
retrospective clinical study [161] 
bile acids promote expression of 
HCV 
Huh7, GS41, HG23 cells [158] 
no effect of bile acids on HCV 
clearance but improvement of 
transaminases 
relative risks, weighted mean 
differences of randomized 
clinical trials 
[182] 
FXR mediated enhancement of 
genotype 1 HCV replication by bile 
acids 
Huh7, Huh7 Lunet cells [159] 
activation of pro-fibrogenic cells by 
bile acids 
clinical study [165] 
association of c.1331T>C of ABCB11 
with fibrosis progression in HCV 
retrospective clinical study [166] 
association of serum bile salts levels 
with sustained virological response 
retrospective clinical study [162] 
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Figure 1: Overview on key transporters involved in hepatocellular bile formation 
Bile salts are predominantly taken up by the sodium taurcholate cotransporting polypeptide 
(NTCP) and and t a minor extent by the organic anion transporting polypeptides (OATPs), 
which work sodium-independent. OATPs are also key drug uptake systems. Bile salts are 
secreted into the canaliculus by the bile salt export pump (BSEP), while the biliary lipids 
phosphatidylcholine and cholesterol require the multidrug resistance protein 3 (MDR3) and 
the heterodimeric transporter ABCG5/ABCG8, respectively. In normal physiologic states the 
nuclear receptor FXR acts as bile salt sensod and downregulates the expression of NTCP 
indirectly and upregulates expression of BSEP directly. Drugs can inhibit BSEP from the 
cytoplasmic side directly and indirectly from the canaliculus in a process requiring functional 
MRP2 (trans-inhibition, right lower insert). Single nucleotide polymorphisms of the ABCB1 
gene with clinical implications for drug-induced cholestasis, intrahepatic cholestasis of 
pregnancy and viral hepatitis C are displayed in a topographical scheme (right upper insert). 
In livers infected with hepatits C virus (HCV), bile salts interfere with interferon signaling 
and promote HCV replication in an FXR-mediated manner (left insert). 
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